TRU-SENTIMENT · DeltaNeutral
CORT Trading Analysis - 11/10/2026 02:55 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
CORT (Corcept Therapeutics Inc.) at $71.90. True Sentiment Bullish, delta 40-60 call 95% / put 5%, call $4,999,900 vs put $253,760. RSI 8.5.
- Symbol
- CORT
- Price
- $71.90
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- low
- Published
- 2026-11-10 14:55:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Options flow (Delta 40-60 only): Call $4,999,900 (95.2%), Put $253,760 (4.8%), Sentiment Bullish. Contracts: 5,514 calls vs 208 puts. 10 call trades, 1 put trade.
Conviction: Extreme call-leaning directional bet despite price near 52-week low-third. Divergence: technicals bearish/oversold, sentiment bullish — matches option-spread engine "divergence detected" note.
Key Statistics: CORT
Fundamental Snapshot
Valuation
| P/E (trailing) | 48.20 |
| EPS (trailing 12 mo) | $1.51 |
| Market cap | $7.87B |
| Shares outstanding | 109.4M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.34 |
| 52-week low | $28.66 |
| 52-week high | $126.38 |
| Historical volatility | 80.8% |
Ownership & trading
| Institutional ownership | 39.3% |
| Average daily volume | 1.2M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context:
Corcept Therapeutics (CORT) has historically been a developer of cortisol-modulating therapies, with its lead product Korlym and pipeline candidates in oncology and metabolic disease often driving sentiment. Using general knowledge (not from embedded data), recent relevant context includes:
- Positive Phase 2/3 data readouts for relacorilant in Cushing's syndrome and prostate cancer have previously acted as upside catalysts for CORT.
- FDA-related developments or advisory panel outcomes for cortisol receptor antagonists remain key binary events that can sharply move the stock.
- Biotech sector rotation and interest-rate sensitivity have pressured small/mid-cap pharma names, potentially contributing to broad weakness.
- No confirmed imminent earnings date is known from this context, but seasonal catalysts (medical conferences) often surface in H2.
Contextually, the embedded data shows a severe drawdown from ~$122 to ~$74 over recent weeks, coinciding with extreme options bullishness — suggesting possible speculative repositioning or recovery bets despite weak price action.
Fundamental Analysis:
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E: 48.20; Trailing EPS: $1.51 — valuation is elevated vs. broad market but typical for biotech with binary pipeline risk.
- Market Cap: $7.87B; Shares Outstanding: 109,443,000; Dividend Yield: 0.00% (no income).
- Beta: 0.34 (low systemic risk); 52-Week Range: $28.66 – $126.38 (current ~$74 is near lower third).
- Institutional Ownership: 39.31% — moderate; Average Volume: 1,223,000.
- Historical Volatility: 80.85% — very high realized vol.
- Missing fields: Revenue Growth, Margins, ROE, D/E, FCF, PEG, Forward PE, Analyst Target — unavailable in data.
Fundamentals show a profitable-but-richly-valued biotech with low beta and no dividend. The steep price decline is not explained by provided fundamental deterioration, creating divergence from the bullish options sentiment.
Current Market Position:
Current price per indicators: $74.29 (as of 2026-11-09 close). Minute bars show 2026-11-09 open $73.31, low $70.51, close $74.29; 2026-11-10 intraday faded from $72.61 (14:05) to $71.90 (14:25) on rising volume (21,065).
Intraday momentum on 2026-11-10 is negative (lower highs/lows, volume expanding into weakness).
Technical Analysis:
Technical Indicators
Price is below all SMAs (bearish stack: 5 < 20 < 50). RSI 8.53 = deeply oversold. MACD negative and histogram worsening. Bollinger mid $94.40, price beneath lower band proximity ($61.13 lower). 30-day range $70.51–$122.81; price near bottom.
True Sentiment Analysis (Delta 40-60 Options):
Options flow (Delta 40-60 only): Call $4,999,900 (95.2%), Put $253,760 (4.8%), Sentiment Bullish. Contracts: 5,514 calls vs 208 puts. 10 call trades, 1 put trade.
Conviction: Extreme call-leaning directional bet despite price near 52-week low-third. Divergence: technicals bearish/oversold, sentiment bullish — matches option-spread engine "divergence detected" note.
Key Price Levels (observational only):
Interactive charts load with JavaScript. This text is the crawlable summary.